CRISPR Therapeutics AG CRSP shares moved lower Tuesday after the biotechnology company outlined plans to raise capital ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

CRISPR Therapeutics (NASDAQ: CRSP) is a company that can potentially help revolutionize healthcare. Its gene-editing therapies can be game changers for patients living with illnesses and conditions ...

ARK Invest purchased ~281K CRISPR Therapeutics (CRSP) shares worth $14.82M after a 10% drop triggered by a $350M private offering announcement.

CRISPR Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating ...

This article looks at the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026. ARK Investment Management LLC, or ARK ...

CRISPR Therapeutics AG (NASDAQ:CRSP) also received a rating update from JPMorgan on February 16. The firm cut the price ...

CRISPR Therapeutics recently reported that rollout of its approved gene therapy Casgevy for sickle cell disease and transfusion‑dependent beta thalassemia has been slower than hoped, contributing to a ...

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its ...

In the latest close session, CRISPR Therapeutics AG (CRSP) was down 5.44% at $49.93. This move lagged the S&P 500's daily loss of 0.08%. On the other hand, the Dow registered a loss of 0.61%, and the ...

Casgevy is starting to build some serious sales momentum. CRISPR Therapeutics also has a deep pipeline and healthy funding. The stock requires patience, but there is a visible path to a bright future.

They're names worth holding for far longer, but the coming decade could prove particularly fruitful for these companies.